Although HNK treatment at the early stage suppressed the development of NASH in MUP-uPA mice, HNK treatment for the last 8 weeks of HCC development clarified its anti-tumor effects independently, at least in part of NASH improvement. The gene discussed is PLAU; the disease is metabolic dysfunction-associated steatohepatitis.